Differences in the pharmacokinetics of gentamicin between oncology and non-oncology paediatric patients.
Dosing gentamicin in paediatric patients can be difficult due to its narrow therapeutic index. A significantly higher percentage fat-mass has been observed in children receiving oncology treatment compared to those who are not. Differences in the pharmacokinetics of gentamicin between oncology and non-oncology paediatric patients and individual dosage requirements were evaluated in this study using normal-fat mass (NFM) as a body size descriptor. Data from 423 oncology and 115 non-oncology patients were analysed. Differences in drug disposition were observed between the oncology and non-oncology patients, with oncology patients having a 16% lower central volume of distribution and 32% lower inter-compartmental clearance. Simulations based on the population pharmacokinetic model demonstrated low exposure target attainment in all individuals at the current clinical recommended starting dose of 7.5 mg/kg once daily: with 57.4% of oncology and 35.7% of non-oncology subjects achieving a peak concentration (Cmax) ≥25mg/L; and 64.3% of oncology and 65.6% of non-oncology subjects achieving an area under the concentration-time curve (AUC24) ≥70 mg⋅h/L after the first dose. Based on simulations, the extent of impact of differences in drug disposition between the two cohorts appeared to be dependent on the exposure target under examination. Greater differences in achieving a Cmax target of >25 mg/L compared to an AUC24 target of ≥70 mg⋅h/L between the cohorts was observed. Further investigation into whether differences in the pharmacokinetics of gentamicin between oncology and non-oncology patients is a consequence of changes in body composition is required.